{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:35:09Z","timestamp":1785785709458,"version":"3.56.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004388","name":"Teva Pharmaceuticals USA Inc West Chester Research and Development Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004388","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jtct.2022.05.022","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T23:59:48Z","timestamp":1653004788000},"page":"486.e1-486.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2061-8126","authenticated-orcid":false,"given":"Scott R.","family":"Solomon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2249-8589","authenticated-orcid":false,"given":"Stacey","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7666-6824","authenticated-orcid":false,"given":"Nancy","family":"Shegda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelin C.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2707-8927","authenticated-orcid":false,"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Bashey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Kent","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5030-7591","authenticated-orcid":false,"given":"Lawrence E.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melhem","family":"Solh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.05.022_bib0001","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.05.022_bib0002","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2017.4600","article-title":"Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis","volume":"4","author":"Dhakal","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtct.2022.05.022_bib0003","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.05.022_bib0004","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1016\/S2352-3026(19)30023-7","article-title":"Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial","volume":"6","author":"Bashir","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2022.05.022_bib0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/sonc.2002.34872","article-title":"Metabolism and mechanisms of action of bendamustine: rationales for combination therapies","volume":"29","author":"Gandhi","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jtct.2022.05.022_bib0006","first-page":"1287","article-title":"The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy","volume":"90","author":"Knop","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.05.022_bib0007","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hon.2546","article-title":"Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients","volume":"36","author":"Farag","year":"2018","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.05.022_bib0008","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1038\/s41409-019-0587-0","article-title":"High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma","volume":"54","author":"Gomez-Arteaga","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.05.022_bib0009","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/bmt.2016.94","article-title":"A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy","volume":"51","author":"Martino","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.05.022_bib0010","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2011-04-351924","article-title":"BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant\/relapsed lymphoma patients","volume":"118","author":"Visani","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.05.022_bib0011","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.05.022_bib0012","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/cncr.20294","article-title":"Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma","volume":"100","author":"Anagnostopoulos","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.05.022_bib0013","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1365-2141.2005.05641.x","article-title":"High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study","volume":"130","author":"Fenk","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.05.022_bib0014","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.leu.2404003","article-title":"Results of a phase I\/II trial adding carmustine (300 mg\/m2) to melphalan (200 mg\/m2) in multiple myeloma patients undergoing autologous stem cell transplantation","volume":"20","author":"Comenzo","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.05.022_bib0015","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3324\/haematol.2010.028027","article-title":"Busulfan 12 mg\/kg plus melphalan 140 mg\/m2 versus melphalan 200 mg\/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA\/GEM2000 study","volume":"95","author":"Lahuerta","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.05.022_bib0016","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2009-06-229658","article-title":"Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)","volume":"115","author":"Roussel","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.05.022_bib0017","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/bmt.2010.160","article-title":"Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma","volume":"46","author":"Kazmi","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.05.022_bib0018","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bbmt.2012.08.009","article-title":"Intravenous busulfan and melphalan as a conditioning regimen for autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: a matched comparison to a melphalan-only approach","volume":"19","author":"Blanes","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.05.022_bib0019","first-page":"398","article-title":"Bortezomib and high-dose melphalan vs. high-dose melphalan as conditioning regimen before autologous stem cell transplantation in de novo multiple myeloma patients: a phase 3 study of the Intergroupe Francophone Du Myelome (IFM 2014-02)","volume":"130","author":"Roussel","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.05.022_bib0020","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.05.022_bib0021","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722013136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722013136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:02:32Z","timestamp":1763002952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722013136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S2666636722013136"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.05.022","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}